Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Prn1371

    DEVELOPMENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Prn1371, 1802929-43-6, Prn-1371, S3ope9ia3q, 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one, Unii-s3ope9ia3q
    Molecular Formula
    C26H30Cl2N6O4
    Molecular Weight
    561.5  g/mol
    InChI Key
    PUIXMSRTTHLNKI-UHFFFAOYSA-N
    FDA UNII
    S3OPE9IA3Q
    pan FGFR Inhibitor PRN1371 is a highly specific covalent inhibitor of human fibroblast growth factor receptor types 1, 2, 3 and 4 (FGFR1-4) with potential antiangiogenic and antineoplastic activities. FGFR1-4 tyrosine kinase inhibitor PRN1371 specifically binds to a conserved cysteine residue in the glycine-rich loop in FGFRs and inhibits their tyrosine kinase activity, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation, proliferation and survival, and in tumor angiogenesis. This agent potently inhibits FGFR1-4 but does not inhibit other tyrosine kinases, even those that share the conserved cysteine, which may improve therapeutic responses and decrease toxicity when compared with less selective inhibitors.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one
    2.1.2 InChI
    InChI=1S/C26H30Cl2N6O4/c1-5-20(35)33-11-9-32(10-12-33)7-6-8-34-24-16(15-30-26(29-2)31-24)13-17(25(34)36)21-22(27)18(37-3)14-19(38-4)23(21)28/h5,13-15H,1,6-12H2,2-4H3,(H,29,30,31)
    2.1.3 InChI Key
    PUIXMSRTTHLNKI-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CNC1=NC=C2C=C(C(=O)N(C2=N1)CCCN3CCN(CC3)C(=O)C=C)C4=C(C(=CC(=C4Cl)OC)OC)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    S3OPE9IA3Q
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido(2,3-d)pyrimidin-7(8h)-one

    2. Prn1371

    2.3.2 Depositor-Supplied Synonyms

    1. Prn1371

    2. 1802929-43-6

    3. Prn-1371

    4. S3ope9ia3q

    5. 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-(4-prop-2-enoylpiperazin-1-yl)propyl]pyrido[2,3-d]pyrimidin-7-one

    6. Unii-s3ope9ia3q

    7. Gtpl9788

    8. Chembl4068509

    9. Schembl16993012

    10. Us9567334, Example 6

    11. Prn 1371 [who-dd]

    12. Bdbm286984

    13. Bcp20493

    14. Ex-a2927

    15. Nsc801089

    16. S8578

    17. Ccg-270053

    18. Cs-7485

    19. Nsc-801089

    20. Compound 34 [pmid: 28665128]

    21. Ac-35543

    22. Bp179867

    23. Hy-101768

    24. J3.662.238e

    25. C92492

    26. A936037

    27. Q29213602

    28. Pyrido(2,3-d)pyrimidin-7(8h)-one, 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-(3-(4-(1-oxo-2-propen-1-yl)-1-piperazinyl)propyl)-

    2.4 Create Date
    2016-02-23
    3 Chemical and Physical Properties
    Molecular Weight 561.5 g/mol
    Molecular Formula C26H30Cl2N6O4
    XLogP33.5
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count9
    Exact Mass560.1705588 g/mol
    Monoisotopic Mass560.1705588 g/mol
    Topological Polar Surface Area100 Ų
    Heavy Atom Count38
    Formal Charge0
    Complexity870
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.